[Studies of anti-lymphocyte antibodies, with special reference to anti-B cell antibodies in choriocarcinoma].
For the purpose of elucidation of the immunologic properties of anti-lymphocyte antibodies which appeared in sera of choriocarcinoma patients, HLA typing of lymphocytes, complement-dependent lymphocytotoxicity test (CT) and mixed lymphocyte reaction (MLR)-blocking assay with patients' sera were performed in 7 couples with the disease. The results obtained were as follows: HLA distribution characteristic of patients and their husbands was not observed. In 3 of 7 patients, their sera exhibited positive CT to their husband's lymphocyte. In MLR-blocking assay, a significant blocking effects (BE) with sera were detected in all patients. The serum BE tended to be sustained for 4 to 8 months even after the decline of serum beta-hCG into the negative range. It was also observed that a case in whom the BE was positive for a longer period of time in a state of remission eventually underwent recurrence. It was demonstrated that the BE and MLR was induced by serum IgG antibodies closely associated with surface antigens of the husband's B-lymphocyte. Consequently, it was strongly suggested that serum anti-lymphocyte antibodies immunologically reflect the tumour burden in choriocarcinoma patients.
D000328:Adult; D000961:Antilymphocyte Serum / Q000032:analysis*; D001402:B-Lymphocytes / Q000276:immunology*; D002822:Choriocarcinoma / Q000276:immunology*; D003601:Cytotoxicity Tests, Immunologic; D005260:Female; D006680:HLA Antigens / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D011247:Pregnancy; D014594:Uterine Neoplasms / Q000276:immunology*
D000961:Antilymphocyte Serum; D006680:HLA Antigens